3-(β,β-dimethylvinyl)quinoline | 102210-66-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-(β,β-dimethylvinyl)quinoline
• 英文别名: 3-(2-Methyl-propenyl)-quinoline；3-(2-methylprop-1-enyl)quinoline
• CAS: 102210-66-2
• 化学式: C₁₃H₁₃N
• 分子量: 183.253
• InChiKey: HUJXHLCTMRQNIP-UHFFFAOYSA-N

物化性质

• 沸点：
  298.8±9.0 °C(Predicted)
• 密度：
  1.052±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-烯丙基-1H-吲哚 在 氢氧化钾 、 bis(triphenylphosphine)nickel(II) chloride 、 二苯并-18-冠醚-6 、 甲基碘化镁 作用下， 以 乙醚 、 苯 为溶剂， 反应 35.0h， 生成 3-(β,β-dimethylvinyl)quinoline
  参考文献：
  名称：

  Synthesis of prenylated indoles

  摘要：

  DOI：

  10.1021/jo00362a031

文献信息

• ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080125444A1

  公开（公告）日：2008-05-29

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• OXIMYL HCV SERINE PROTEASE INHIBITORS
  申请人：GAI YONGHUA

  公开号：US20090155210A1

  公开（公告）日：2009-06-18

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
  申请人：GAI YONGHUA

  公开号：US20090197888A1

  公开（公告）日：2009-08-06

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US7728148B2
  申请人：——

  公开号：US7728148B2

  公开（公告）日：2010-06-01
• US8361958B2
  申请人：——

  公开号：US8361958B2

  公开（公告）日：2013-01-29

表征谱图